WHO ICTRP trial
A single-center, open-label, Phase I clinical trial to evaluate the safety…
JPRN-jRCT2021250018 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2021250018 |
|---|---|
| Public title | A single-center, open-label, Phase I clinical trial to evaluate the safety, efficacy, and pharmacokinetics of 211At-NpG-PSMA radioligand therapy in patients with castration-resistant prostate cancer |
| Scientific title | A single-center, open-label, Phase I clinical trial to evaluate the safety, efficacy, and pharmacokinetics of 211At-NpG-PSMA radioligand therapy in patients with castration-resistant prostate cancer - A single-center, open-label, Phase I clinical trial to evaluate the safety, efficacy, and… |
| Primary sponsor | Kojima Yoshiyuki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Conditions | Castration-Resistant Prostate Cancer |
| Interventions | The investigational product will be administered as a single intravenous dose. The initial dose level will be Cohort 1 (0.39 MBq/kg). Subsequent dose escalation will proceed to Cohort 2 (0.78 MBq/kg) and Cohort 3 (1.17 MBq/kg) in accordance… |
| Registration date | Dec 9, 2025 |
| Target size | 18 |
| Registry page | jrct.mhlw.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: